Dr. Ken Cadesky MD, FRCSC
Medical Director and Founding Partner
Dr. Ken Cadesky, a Reproductive Gynecologist for over 25 years, completed his Fellowship training in Obstetrics and Gynecology at the University of Toronto and the University of British Columbia and subsequently completed a Fellowship in Prenatal Genetics and Reproductive Endocrinology at the University of British Columbia and the University of Maryland School of Medicine in Baltimore.
Dr. Cadesky is a founding partner of S.T.A.R.T. (Success Through Assisted Reproductive Technologies), LifeQuest Centre for Reproductive Medicine, and Founding Partner and Medical Director of TRIO Fertility.
In addition to his practice at TRIO, Dr. Cadesky is an Assistant Professor in the Department of Obstetrics and Gynecology and a member of the Division of Reproductive Endocrinology and Infertility (REI) at the University of Toronto.
Dr. Cadesky also holds the position of Staff Physician at Mount Sinai Hospital and the University Health Network, and he is certified in both abdominal laser surgery and abdominal/pelvic ultrasound.
Dr. Cadesky is currently a member of the IVF Directors section and the Board of Directors of the Canadian Fertility and Andrology Society (CFAS). He is also Vice Chairman of the REI division of the Ontario Medical Association.
His current research interests include studies in embryo implantation, improvement in low ovarian responder protocols, and Pre-implantation Genetic Testing (PGT) of embryos. He is co-author of numerous peer-reviewed research papers on a range of topics in the field of Reproductive Medicine.
Why I Love Being A Fertility Doctor
"I’ve had the privilege of being involved in the field of fertility medicine from its very early days. And I've been lucky enough to have seen techniques improve and success rates increase steadily. It’s very exciting because fertility medicine is constantly changing and improving, and that means not only am I learning something new all the time, but more importantly, I’m able to offer new approaches and innovative treatment options to patients on a regular basis.”